Kathwate Gunderao H
Department of Biotechnology, Savitribai Phule Pune University, Pune, Maharashtra India.
Int J Pept Res Ther. 2022;28(1):37. doi: 10.1007/s10989-021-10348-z. Epub 2022 Jan 3.
COVID 19 is a disease caused by a novel coronavirus, SARS-CoV2 originated in China most probably of Bat origin. Multiepitopes vaccine would be useful in eliminating SARS-CoV2 infections as asymptomatic patients are in large numbers. In response to this, we utilized bioinformatic tools to develop an efficient vaccine candidate against SARS-CoV2. The designed vaccine has effective BCR and TCR epitopes screened from the sequence of S-protein of SARS-CoV2. Predicted BCR and TCR epitopes found antigenic, non-toxic and probably non-allergen. Modeled and the refined tertiary structure predicted as valid for further use. Protein-Protein interaction prediction of TLR2/4 and designed vaccine indicates promising binding. The designed multiepitope vaccine has induced cell-mediated and humoral immunity along with increased interferon-gamma response. Macrophages and dendritic cells were also found to increase upon the vaccine exposure. In silico codon optimization and cloning in expression vector indicates that the vaccine can be efficiently expressed in . In conclusion, the predicted vaccine is a good antigen, probable no allergen, and has the potential to induce cellular and humoral immunity.
新冠病毒病是由一种新型冠状病毒，即严重急性呼吸综合征冠状病毒2（SARS-CoV2）引起的疾病，该病毒极有可能起源于中国的蝙蝠。由于大量患者为无症状感染者，多表位疫苗对于消除SARS-CoV2感染将很有用。对此，我们利用生物信息学工具开发了一种针对SARS-CoV2的高效候选疫苗。所设计的疫苗具有从SARS-CoV2的S蛋白序列中筛选出的有效的B细胞受体（BCR）和T细胞受体（TCR）表位。预测的BCR和TCR表位具有抗原性、无毒且可能无致敏性。建模并优化后的三级结构经预测可有效用于后续研究。Toll样受体2/4（TLR2/4）与所设计疫苗的蛋白质-蛋白质相互作用预测显示出有前景的结合。所设计的多表位疫苗可诱导细胞介导的免疫和体液免疫，同时增加γ干扰素反应。疫苗接种后还发现巨噬细胞和树突状细胞有所增加。计算机辅助密码子优化及在表达载体中的克隆表明该疫苗可在……中高效表达。总之，预测的疫苗是一种良好的抗原，可能无致敏性，并且有诱导细胞免疫和体液免疫的潜力。
